Clinical Trial Search

Primary: The Primary End Point of the Study Was the Mean/Median Number of Days Postsurgery Required for Each Group to Return to 100% Functioning Capacity. — 43; 45 days

Primary: Successful Completion of the Surgical Procedure — 3 Participants

Primary: Percent Change From Baseline in eGFR — -10.7; -9.4 percent change in eGFR

Primary: Successful Capture of IO-CEUS Images — 10 participants

Primary: Follow-up Duration — 1.07 years

Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to 6 Months — -8.5; -8.4 % change from preoperative eGFR

Primary: Response Rate — 8 Participants

Primary: "Second Look" Rate — 4; 56; 56; 118 Participants — p=<0.01

Primary: Pain 'Right Now' — 2.4; 3.1 units on a scale

Primary: Proportion of Vessels Transected Requiring Intra-Operative Hemostatic Interventions — 0.1359; 0.1836 proportion of transected vessels

Primary: Acute Procedural Safety — 4 percentage of participants

Primary: Safety of Sunitinib Malate (SM) — .350 proportion of participants

Primary: Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT) — 76.1; 25.0; 87.5 Percentage of 4-year OS — p=.0199

Primary: Disease-free Survival — 192; 197 Participants — p=0.737

Primary: Maximum Tolerated Dose of Radiosurgery — 48; 60 Gy

Primary: Disease-Free Survival (DFS) by BICR - Treatment Part A and B — NA; NA; NA; NA Months — p=0.6676

Primary: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens — 10 Participants

Primary: Changes in Glomerular Renal Function After Weight Loss Surgery as Measured by 51Cr-EDTA Clearance — 0 Participants

Primary: Disease-free Survival (DFS) — 5.8; 6.1; 6.6 years — p=0.80

Primary: Visual Analog Scale (VAS) Pain Scores — 4.5; 5; 1; 1 score on a scale

Primary: Urinary Tract Infection After Percutaneous Nephrostomy Procedure — 5; 10 Percutaneous nephrostomy procedure — p=0.548

Primary: Percentage of Participants Who Achieved a Point in Time Objective Response (Either Complete or Partial Response [CR or PR]) Prior to Surgery — 2; 0 Participants

Primary: Response to Sunitinib Therapy — 13 participants

Primary: Percentage of Participants Who Died — 67.3; 69.6 percentage of participants

Primary: 5-year Recurrence-free Survival (RFS) — 63; 67 percentage of paticipants

Primary: Disease-free Survival (DFS) as Assessed by the Investigator — NA; NA Months — p=0.0010

Primary: Number of Participants With Pathologically Proven Lymph Node Metastasis — 1 participants

Primary: Postoperative Analgesic (Tramadol) Consumption

Primary: Primary Effectiveness: Technical Success — 100.0 percentage of tumors

Primary: Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo — NA; NA months — p=0.1649